Evidence Hub

Nasal Bleeding as a Potential Side Effect of Omega-3 Fatty Acids: A Case Report

Abdul-Nabi ZN

Current drug safety, 2026

Abstract

BACKGROUND

Omega-3 fatty acids (omega-3 FAs) have been studied for the potential treatment of Atopic Dermatitis (AD). Dietary supplementation with omega-3 FAs may help in reducing AD symptoms, including the severity of lesions, inflammation, dryness, and pruritus. Nevertheless, because of their antiplatelet action, more cautious use of these supplements has been recommended in patients who have an invasive procedure or who are receiving antiplatelet or anticoagulant therapy.

CASE PRESENTATION

An 18-year-old male patient with AD self-medicated with 1 gram of overthe-counter omega-3 fatty acid orally once daily for 4 weeks. Over this time, he had ten episodes of epistaxis. Baseline coagulation parameters, such as prothrombin time, activated partial thromboplastin time, and platelet count, were also normal. The patient was not on medications affecting the hemostatic process, nor were there any previous polyps or other structural nasal disorders.

CONCLUSIONS

The potential of omega-3 FA supplementation to increase risk of bleeding, even at typical doses used in clinical trials, should be considered as demonstrated in this case.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free